Dana Song, Sammy Saab
Long‐term outcomes with oral therapy in liver transplant recipients with hepatitis B
Objective: The present study evaluates how oral antiviral agents impact long-term renal function in liver transplant recipients with a history of Hepatitis B.
Methods: We studied 79 patients who received a liver transplant for hepatitis B and were placed on all-oral antiviral therapy after withdrawing from hepatitis B immunoglobulin therapy at a single-institution tertiary care center. A retrospective chart review was conducted to obtain laboratory data. Univariate and two-sided t tests were performed.
Results: 22.8% (18/79) of recipients on any all-oral therapy regimen had worsening of their chronic kidney disease stage, and 17.7% (14/79) had an increase in creatinine of at least 0.3 mg/dL. There were no significant changes in creatinine and GFR in patients while on tenofovir alafenamide.
Conclusion: Oral antiviral agents generally worsen renal function in liver transplant recipients with a history of hepatitis B. However, tenofovir alafenamide appears to have less of an impact on renal function compared to other oral antiviral agents.